Novavax Covid-19 vaccine elicits immune response in early trial
New York: A Covid-19 vaccine developed by US-based Novavax elicited robust antibody responses and appeared to be safe in a Phase-I human trial, the company has said. No serious adverse events …
Novavax Covid-19 vaccine elicits immune response in early trial Read More